- Home
- CYCN vs MBRX Comparison
CYCN vs MBRX Comparison
Compare CYCN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- MBRX
- Stock Information
- Founded
- CYCN 2018
- MBRX 2015
- Country
- CYCN United States
- MBRX United States
- Employees
- CYCN N/A
- MBRX N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- MBRX Health Care
- Exchange
- CYCN Nasdaq
- MBRX Nasdaq
- Market Cap
- CYCN 8.5M
- MBRX 7.0M
- IPO Year
- CYCN N/A
- MBRX 2016
- Fundamental
- Price
- CYCN $3.32
- MBRX $1.79
- Analyst Decision
- CYCN
- MBRX Strong Buy
- Analyst Count
- CYCN 0
- MBRX 2
- Target Price
- CYCN N/A
- MBRX $24.00
- AVG Volume (30 Days)
- CYCN 9.1M
- MBRX 62.4K
- Earning Date
- CYCN 11-14-2024
- MBRX 11-08-2024
- Dividend Yield
- CYCN N/A
- MBRX N/A
- EPS Growth
- CYCN N/A
- MBRX N/A
- EPS
- CYCN N/A
- MBRX N/A
- Revenue
- CYCN $194,000.00
- MBRX N/A
- Revenue This Year
- CYCN N/A
- MBRX N/A
- Revenue Next Year
- CYCN N/A
- MBRX N/A
- P/E Ratio
- CYCN N/A
- MBRX N/A
- Revenue Growth
- CYCN N/A
- MBRX N/A
- 52 Week Low
- CYCN $1.27
- MBRX $0.40
- 52 Week High
- CYCN $9.47
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- CYCN 52.12
- MBRX 38.52
- Support Level
- CYCN $2.80
- MBRX $1.50
- Resistance Level
- CYCN $3.43
- MBRX $3.10
- Average True Range (ATR)
- CYCN 0.71
- MBRX 0.26
- MACD
- CYCN -0.07
- MBRX -0.06
- Stochastic Oscillator
- CYCN 19.26
- MBRX 23.65
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.